Kevin McElwee - RepliCel Life Chief Scientific Officer

RP Stock  CAD 0.01  0.00  0.00%   

Executive

Dr. Kevin McElwee, Ph.D., serves as Chief Scientific Officer of RepliCel Life Sciences Inc. Dr. McElwee is an Associate Professor in the Department of Dermatology and Skin Health at the University of British Columbia, and Director of the Hair Research Laboratory in the Vancouver Coastal Health Research Institute at Vancouver General Hospital . His research is funded by competitive grants awarded by multiple organizations including the Canadian Institute for Health Research . Dr. McElwee is one of only a small group of research scientists worldwide who studies hair biology and associated diseases. He has worked as a hair research scientist for 12 years and has published over 70 medical journal articles, research abstracts and academic book chapters on hair loss research since 2010.
Age 54
Tenure 14 years
Professional MarksPh.D
Address 570 Granville Street, Vancouver, BC, Canada, V6C 3P1
Phone604 248 8730
Webhttps://www.replicel.com
McElwee received his BS degree from the University of Aberdeen, Scotland and his PhD from the University of Dundee, Scotland. Postdoctoral training included three years at the Jackson Laboratory in Maine and four years at the University of Marburg, Germany, studying various hair loss diseases.

RepliCel Life Management Efficiency

The company has return on total asset (ROA) of (1.5334) % which means that it has lost $1.5334 on every $100 spent on assets. This is way below average. RepliCel Life's management efficiency ratios could be used to measure how well RepliCel Life manages its routine affairs as well as how well it operates its assets and liabilities. At this time, RepliCel Life's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.07 in 2024, whereas Return On Tangible Assets are likely to drop (1.14) in 2024. At this time, RepliCel Life's Other Current Assets are fairly stable compared to the past year. Debt To Assets is likely to climb to 3.19 in 2024, whereas Non Current Assets Total are likely to drop slightly above 119.4 K in 2024.
RepliCel Life Sciences currently holds 813.19 K in liabilities. RepliCel Life Sciences has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist RepliCel Life until it has trouble settling it off, either with new capital or with free cash flow. So, RepliCel Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RepliCel Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RepliCel to invest in growth at high rates of return. When we think about RepliCel Life's use of debt, we should always consider it together with cash and equity.
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada. REPLICEL LIFE operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange. RepliCel Life Sciences (RP) is traded on TSX Venture Exchange in Canada and employs 8 people. RepliCel Life is listed under Biotechnology category by Fama And French industry classification.

Management Performance

RepliCel Life Sciences Leadership Team

Elected by the shareholders, the RepliCel Life's board of directors comprises two types of representatives: RepliCel Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RepliCel. The board's role is to monitor RepliCel Life's management team and ensure that shareholders' interests are well served. RepliCel Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RepliCel Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
BA CPA, Chief Officer
Kevin McElwee, Chief Scientific Officer
MSc PMP, Clinical Consultant
Ben Austring, Corporate Officer
David CPA, Chief Officer
Andrew Schutte, CEO President
BEd LLB, Corp Director
Rolf MD, Chief Board

RepliCel Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RepliCel Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for RepliCel Stock Analysis

When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.